AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation.

Gowans GJ, Hawley SA, Ross FA, Hardie DG. · 2013

Read AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. by Gowans GJ, Hawley SA, Ross FA, Hardie DG. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3791399.txt.

Introduction

Graeme Gowans, Simon Hawley, Fiona Ross, and D. Grahame Hardie reported a study in Cell Metabolism in 2013 on AMP-activated protein kinase, or AMPK. AMPK senses a cell's energy state and restores balance by switching on fuel-making paths and switching off fuel-using ones. A dispute had arisen over which molecule truly controls it in living cells, AMP or its relative ADP.

The team found that AMP is about ten times stronger than ADP at protecting the kinase's key activation site from being stripped. Only AMP boosted the site's phosphorylation by its upstream kinase, and AMP alone could raise activity more than tenfold at levels far below those of ATP. They also showed allosteric activation raising downstream targets in intact cells. The authors conclude AMP is the true physiological regulator.

Catalog record

CREATORGowans GJ, Hawley SA, Ross FA, Hardie DG.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3791399

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation By Graeme J. Gowans, Simon A. Hawley, Fiona A. Ross, D. Grahame Hardie Published in: Cell Metabolism DOI: 10.1016/j.cmet.2013.08.019 ABSTRACT Summary While allosteric activation of AMPK is triggered only by AMP, binding of both ADP and AMP has been reported to promote phosphorylation and inhibit dephosphorylation at Thr172. Because cellular concentrations of ADP and ATP are higher than AMP, it has been proposed that ADP is the physiological signal that promotes phosphorylation and that allosteric activation is not significant in vivo. However, we report that: AMP is 10-fold more potent than ADP in inhibiting Thr172 dephosphorylation; only AMP enhances LKB1-induced Thr172 phosphorylation; and AMP can cause >10-fold allosteric activation even at concentrations 1–2 orders of magnitude lower than ATP. We also provide evidence that allosteric activation by AMP can cause increased phosphorylation of acetyl-CoA carboxylase in intact cells under conditions in which there is no change in Thr172 phosphorylation. Thus, AMP is a true physiological regulator of AMPK, and allosteric regulation is an important component of the overall activation mechanism. INTRODUCTION AMP-activated protein kinase (AMPK) is a sensor of cellular energy status expressed ubiquitously in almost all eukaryotic cells. Once activated by metabolic stresses that inhibit ATP production or accelerate ATP consumption, it triggers metabolic changes that act to restore energy homeostasis, switching on catabolic pathways that generate ATP while inhibiting anabolic pathways and other ATP-requiring processes (Hardie et al., 2011; 2012). AMPK exists as heterotrimeric complexes comprising catalytic α subunits and regulatory β and γ subunits, each of which occurs in mammals as alternate isoforms encoded by distinct genes. Phosphorylation of Thr172 within the activation loop of the α subunit kinase domain can cause activation of >100-fold in cell-free assays. The major Thr172 kinase is a complex containing the tumor suppressor kinase LKB1 (liver kinase B1) (Hawley et al., 2003; Shaw et al., 2004; Woods et al., 2003), although many cells display an alternate pathway involving the calmodulin-dependent protein kinase, CaMKKβ (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005). CaMKKβ is activated by increases in intracellular Ca2+, while the LKB1 complex appears to be constitutively active (Lizcano et al., 2004; Sakamoto et al., 2004). However, binding of adenine nucleotides to the γ subunit (Scott et al., 2004; Xiao et al., 2007; 2011) causes conformational changes that regulate the phosphorylation and dephosphorylation of Thr172, and hence AMPK activity, allowing the phosphorylation state to alter according to cellular energy status. The regulatory adenine nucleotide-binding sites on the γ subunits are formed by four tandem CBS repeats (Scott et al., 2004). Crystallography of partial complexes from mammals and fungi (Amodeo et al., 2007; Jin et al., 2007; Townley and Shapiro, 2007; Xiao et al., 2007; 2011) revealed that these have a pseudosymmetrical layout, generating four clefts in the center where adenine nucleotides could bind; these sites are numbered according to which CBS repeat bears an aspartate side chain involved in nucleotide binding (Kemp et al., 2007). In a structure of a mammalian complex crystallized with AMP, site 2 was empty, while sites 1, 3, and 4 were occupied by AMP. When ATP was soaked into the crystals, AMP was replaced by ATP only at sites 1 and 3, so site 4 was designated a nonexchangeable site where AMP was proposed to be permanently bound (Xiao et al., 2007; 2011). Competitive binding studies using fluorescent ATP derivatives suggested that the affinities for binding of AMP, ADP, and ATP at sites 1 and 3 are similar, although site 1 appeared to have an affinity 30- to 40-fold higher than that of site 3 for all three nucleotides (Xiao et al., 2011). Even before the identity of the upstream kinases had been determined, AMP binding had been reported to both promote phosphorylation (Hawley et al., 1995) and inhibit dephosphorylation (Davies et al., 1995) of Thr172. It was recently reported that binding of ADP, as well as AMP, inhibited dephosphorylation (Xiao et al., 2011) and that ADP as well as AMP enhanced phosphorylation of Thr172 by both LKB1 and CaMKKβ (Oakhill et al., 2010; 2011). Based on these findings and the fact that cellular ADP concentrations are usually at least one order of magnitude higher than those of AMP, it was proposed that ADP, not AMP, is the physiological signal that enhances net Thr172 phosphorylation and that allosteric activation by AMP may not be relevant in the physiological context (Carling et al., 2012; Oakhill et al., 2012). In this paper, we have reinvestigated these questions. RESULTS AMP Is More Potent than ADP in Inhibiting Dephosphorylation of Thr172 Native AMPK purified from rat liver has been consistently reported to exhibit a greater allosteric activation by AMP (typically 3- to 4-fold; Carling et al., 1987; 1989) than bacterially expressed rat or human complexes (typically 1.5- to 2-fold; Sanders et al., 2007; Suter et al., 2006). We therefore used purified rat liver AMPK to reinvestigate the regulatory effects of adenine nucleotides in cell-free assays. We first monitored the ability of various concentrations of AMP and ADP to protect against inactivation caused by incubation with recombinant PP2Cα (Figure 1A). This confirmed previous results (Xiao et al., 2011) showing that ADP, as well as AMP, protected against inactivation and dephosphorylation, but AMP was effective at lower concentrations than ADP. In the absence of ATP, the half-maximal effect of AMP on inactivation (EC50) was at 2.6 ± 0.3 μM, whereas the half-maximal effect of ADP was at 23 ± 3 μM, almost 10-fold higher. We repeated the assays in the presence of 5 mM ATP (Figure 1A). As expected if ATP competes with AMP and ADP, the EC50 for AMP increased by 75-fold to 196 ± 15 μM and for ADP by 60-fold to 1.4 ± 0.1 mM. However, the higher potency of AMP compared with that of ADP was retained. At this ATP concentration (which is within the physiological range), the EC50 values for AMP and ADP were 25-fold and 3- to 4-fold lower, respectively, than the ATP concentration. Parallel analysis of Thr172 phosphorylation (Figure 1B) was consistent with the activity assays. Analysis of our commercial preparation of ADP showed that it exhibited ≈1% contamination with AMP. Thus, contamination with AMP was unlikely to explain an effect of ADP that was only 10-fold less potent than that of AMP. However, to rule this out we repeated the assays at saturating concentrations of AMP and ADP with and without the 5′-nucleotidase CD73, which hydrolyzes AMP to adenosine and phosphate, but not ADP or ATP. While the effects of AMP were abolished as expected, the effects of ADP were only partially reduced (Figure 1C). The small reduction may be accounted for by hydrolysis of the small amount of AMP contaminating the ADP, but the residual protection must be due to ADP. AMP, but Not ADP, Enhances Phosphorylation by LKB1, but Not CaMKKβ Both AMP and ADP have recently been reported to enhance phosphorylation of Thr172 by LKB1 and CaMKKβ, as long as the β subunit was N-myristoylated (Oakhill et al., 2010; 2011). Figure 2A shows that AMP promoted activation and Thr172 phosphorylation of rat liver AMPK by LKB1, but not CaMKKβ.

Read the complete text